1. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report;Galluppi;Clin Pharmacol Ther,2001
2. Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man;Geary,2007
3. Modelling pharmacokinetic and pharmacodynamic properties of second generation antisense-oligonucleotides (ASOs);Callies,2007
4. Yu RZ, Gibiansky L, Gibiansky E, Geary RS. Population pharmacokinetics and pharmacodynamics of ISIS 2302 (Role of Population Analysis in Drug Development). ASCPT Annual Meeting. Orlando, Florida; 2001.
5. Yu RZ, Matson J, Geary RS. Terminal elimination rates for antisense oligonucleotides in plasma correlate with tissue clearance rates in mice and monkeys. Annual Meeting of American Association of Pharmaceutical Scientists. Denver, Colorado; 2001.